DV3R Stock Chart & Stats
€9.15
-€0.20(-1.67%)
At close: 4:00 PM EST
€9.15
-€0.20(-1.67%)
Day’s Range― - ―
52-Week Range€7.20 - €12.10
Previous CloseN/A
Volume1.00K
Average Volume (3M)18.00
Market Cap
€379.91M
Enterprise Value€245.88
Total Cash (Recent Filing)€89.30M
Total Debt (Recent Filing)€907.00K
Price to Earnings (P/E)776.9
Beta1.26
Next Earnings
Aug 06, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding34,521,650
10 Day Avg. Volume0
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio3.81
Price to Book (P/B)3.25
Price to Sales (P/S)4.24
P/FCF Ratio17.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.91Price Target Upside117.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.49
Revenue Forecast (FY)€90.44M
Bulls Say, Bears Say
Bulls Say
Robust Clinical Evidence (CHOPIN)High-impact Lancet Oncology CHOPIN results materially strengthen HEPZATO's clinical value proposition, encouraging physician adoption and combination use. Durable improvements in response and survival can expand eligible patient pools and sustain kit demand across multiple treatment settings.
Strong Cash Generation & Low LeverageConsistent positive operating and free cash flow plus a no-debt balance sheet provide durable financial flexibility to fund site expansion, higher R&D and SG&A, and commercial initiatives without immediate need for dilutive financing. This supports long-term execution and resilience to setbacks.
Rapid Revenue Scale-upSustained multi-year revenue expansion demonstrates clear commercial traction for the HEPZATO kit and growing procedure adoption. This scale lowers per-unit fixed costs, supports wider hospital adoption, and creates a larger recurring revenue base that underpins medium-term growth assumptions.
Bears Say
Slower Site Activation & Trial EnrollmentDelayed site activations and sluggish clinical enrollment constrain the rate at which procedure volumes and kit reorders scale. This structural headwind slows revenue predictability, increases reliance on incentives, and can delay network effects that drive sustainable adoption and unit economics.
Rising R&D And SG&A SpendMaterial planned increases in R&D and commercial SG&A are structurally necessary for trials and expansion but will pressure margins and cash conversion if top-line growth or reimbursement improvements lag. Higher fixed costs lengthen the runway to durable adjusted EBITDA.
Thin, Volatile Operating ProfitabilityOperating profit remains fragile, indicating earnings sensitivity to cost increases or slower volume. Thin EBIT creates risk that temporary revenue or margin shocks, or rising commercial and R&D spend, could flip reported profitability negative again, challenging consistent cash returns.
Delcath Systems News
DV3R FAQ
What was Delcath Systems, Inc.’s price range in the past 12 months?
Delcath Systems, Inc. lowest stock price was €7.20 and its highest was €12.10 in the past 12 months.
What is Delcath Systems, Inc.’s market cap?
Delcath Systems, Inc.’s market cap is €379.91M.
When is Delcath Systems, Inc.’s upcoming earnings report date?
Delcath Systems, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were Delcath Systems, Inc.’s earnings last quarter?
Delcath Systems, Inc. released its earnings results on May 07, 2026. The company reported -€0.026 earnings per share for the quarter, beating the consensus estimate of -€0.085 by €0.059.
Is Delcath Systems, Inc. overvalued?
According to Wall Street analysts Delcath Systems, Inc.’s price is currently Undervalued.
Does Delcath Systems, Inc. pay dividends?
Delcath Systems, Inc. does not currently pay dividends.
What is Delcath Systems, Inc.’s EPS estimate?
Delcath Systems, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Delcath Systems, Inc. have?
Delcath Systems, Inc. has 34,521,650 shares outstanding.
What happened to Delcath Systems, Inc.’s price movement after its last earnings report?
Delcath Systems, Inc. reported an EPS of -€0.026 in its last earnings report, beating expectations of -€0.085. Following the earnings report the stock price went down -0.334%.
Which hedge fund is a major shareholder of Delcath Systems, Inc.?
Currently, no hedge funds are holding shares in DE:DV3R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Delcath Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.91 (117.58% Upside)
€19.91 (117.58% Upside)
Blogger Sentiment
Bullish
DE:DV3R Sentiment 70%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.97%
Trailing 12-Months
Company Description
Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
DV3R Stock 12 Month Forecast
Average Price Target
€19.91
▲(117.58% Upside)
Technical Analysis
―
ClearPoint Neuro
―
Senseonics Holdings
―
Nano-X Imaging
―
Treace Medical Concepts
―